Delta-24-RGD (DNX-2401)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Delta-24-RGD (DNX-2401), covering 2015-03-09 to 2015-03-09. Get the full timeline:
Most recent: Clinical Trial Update: Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma [Phase 1, Phase 2]